Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1142-1150

  Dings, Ruud P M ^a   Levine, Joseph I ^a   Brown, Susan G ^a   Astorgues Xerri, Lucile ^b   MacDonald, John R ^c   Hoye, Thomas R ^a   Raymond, Eric ^b   Mayo, Kevin H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BEAUJON HOSPITAL   (France)

^c PepTx Inc   (United States)

Author keywords

Calixarenes; Galectin 1; Structure Activity relationships; Therapeutics

Indexed keywords

CALIXARENE; OTX 008; PTX 008; PTX 009; PTX 012; PTX 013; PTX 014; PTX 015; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CHEMICAL MODIFICATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESISTANCE; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROSARCOMA; G1 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IC 50; IN VIVO STUDY; LUNG CARCINOMA; MELANOMA; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CARCINOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; STRUCTURE ACTIVITY RELATION; UMBILICAL VEIN ENDOTHELIAL CELL; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CALIXARENES; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; CYTOTOXINS; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLASTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TUMOR BURDEN;

EID: 84884817009     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9932-0     Document Type: Article

References (21)

1. Hambley TW, Hait WN (2009) Is anticancer drug development heading in the right direction? Cancer Res 69(4):1259-1262
2. Dings RP, Mayo KH (2007) A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents. Acc Chem Res 40(10):1057-1065
3. Chen X, Dings RP, Nesmelova I, Debbert S, Haseman JR, Maxwell J, Hoye TR, Mayo KH (2006) Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins. J Med Chem 49(26):7754-7765
4. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, Mayo KH (2001) Anginex, a designed peptide that inhibits angiogenesis. Biochem J 354(Pt 2):233-242
5. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ (2007) Scheduling of radiation with angiogenesis inhibitors Anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13(11):3395-3402
6. Dings RP, Van Laar ES, Loren M, Webber J, Zhang Y, Waters SJ, Macdonald JR, Mayo KH (2010) Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug Chem 21(1):20-27
7. Dings RP, van der Schaft DW, Hargittai B, Haseman J, Griffioen AW, Mayo KH (2003) Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett 194(1):55-66
8. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH (2003) The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 63(2):382-385
9. Ortiz Mellet C, Benito JM, Garcia Fernandez JM (2010) Preorganized, macromolecular, gene-delivery systems. Chemistry 16(23):6728-6742
10. Bagnacani V, Franceschi V, Fantuzzi L, Casnati A, Donofrio G, Sansone F, Ungaro R (2012) Lower Rim Guanidinocalix[4]arenes: Macrocyclic Nonviral Vectors for Cell Transfection. Bioconjug Chem 23:993-1002
11. Dings RP, Chen X, Hellebrekers DM, van Eijk LI, Zhang Y, Hoye TR, Griffioen AW, Mayo KH (2006) Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst 98(13):932-936
12. Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH (2012) Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem 55(11):5121-5129
13. Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ (2005) Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 115(2):312-319
14. Dings RP, Loren ML, Zhang Y, Mikkelson S, Mayo KH, Corry P, Griffin RJ (2011) Tumour thermotolerance, a physiological phenomenon involving vessel normalisation. Int J Hyperth 27(1):42-52
15. Fritah A, Saucier C, De Wever O, Bracke M, Bieche I, Lidereau R, Gespach C, Drouot S, Redeuilh G, Sabbah M (2008) Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 28(3):1114-1123
16. Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, Vidaud M, Phillips E, Weill S, Benhadji KA, Lokiec F, Cvitkovic E, Faivre S, Raymond E (2009) Epithelial-to-mesenchymal transition and resistance to ingenol 3-Angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res 69(10):4260-4269
17. De Craene B, Gilbert B, Stove C, Bruyneel E, van Roy F, Berx G (2005) The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res 65(14):6237-6244
18. Griffin RJ, Dings RP, Jamshidi-Parsian A, Song CW (2010) Mild temperature hyperthermia and radiation therapy: role of tumour vascular thermotolerance and relevant physiological factors. Int J Hyperth 26(3):256-263
19. Mayo KH, Dings RP, Flader C, Nesmelova I, Hargittai B, van der Schaft DW, van Eijk LI, Walek D, Haseman J, Hoye TR, Griffioen AW (2003) Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem 278(46):45746-45752
20. Dings RP, Van Laar ES, Webber J, Zhang Y, Griffin RJ, Waters SJ, MacDonald JR, Mayo KH (2008) Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett 265(2):270-280
21. Serova M, Astorgues-Xerri L, Bieche I, Albert S, Vidaud M, Benhadji KA, Emami S, Vidaud D, Hammel P, Theou-Anton N, Gespach C, Faivre S, Raymond E (2010) Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther 9(5):1308-1317